CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

India's Veeda Clinical Research acquires Bioneeds ahead of IPO

By Munikoti Rochan

09:21, 19 July 2021

Ahead of its initial share sale, India's Veeda Clinical Research, a full-service clinical research organisation, said it acquired a 50.1% controlling stake in the privately-held pre-clinical services provider, Bioneeds India.

In a press release on Monday, the west India-based organisation backed by Indian private equity firm CX Partners announced its additional acquisition in Bioneeds, in which it had picked up a minority stake earlier in March.

This acquisition is a precursor to Veeda’s proposed initial public offering (IPO) in the Indian stock markets. The firm said it was in the process of filing IPO-related documents with the markets regulator Securities and Exchange Board of India.

In June, Veeda raised $16m from a clutch of investors including Mumbai-based private equity firm Sabre Partners and some high net worth individuals.

Research destination

The expanding budgetary allocation for research and development in global pharmaceutical companies is the opportunity the research firms looks to capitalise on.

“India is becoming an attractive destination for clinical and preclinical research outsourcing supported by quality scientific capability, emergence of the biosimilars industry, increased demand for complex generics and availability of a large number of patient volunteers,” according to a report by Frost & Sullivan India titled Clinical Research Organisation Market Report, said the press release.

US100

18,249.40 Price
-0.200% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 21:00 (UTC)
Spread 7.0

Gold

2,233.43 Price
+1.740% 1D Chg, %
Long position overnight fee -0.0188%
Short position overnight fee 0.0106%
Overnight fee time 21:00 (UTC)
Spread 0.80

XRP/USD

0.64 Price
+0.450% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01168

BTC/USD

70,183.10 Price
-0.750% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 106.00

Company details

Gujarat-based Veeda conducts complex clinical studies for drug makers and completed several regulatory inspections and is approved by regulators such as the United States Food and Drug Administration, the UK’s Medicines and Healthcare products Regulatory Agency, Brazilian Health Regulatory Agency and by the World Health Organization, said the statement.

In November 2018, a consortium of private equity investors led by India-based private equity player CX Partners acquired a majority stake in Veeda.

South India-based Bioneeds provides discovery, development and regulatory services to the pharmaceutical industry.

 

Read more: Crypto transactions violate forex rules, says Indian agency

Rate this article

Capital Com is an execution-only service provider. The material provided in this article is for information purposes only and should not be understood as investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents and has not been prepared in accordance with the legal requirements designed to promote investment research independence. While the information in this communication, or on which this communication is based, has been obtained from sources that Capital.com believes to be reliable and accurate, it has not undergone independent verification. No representation or warranty, whether expressed or implied, is made as to the accuracy or completeness of any information obtained from third parties. If you rely on the information on this page, then you do so entirely at your own risk.

Still looking for a broker you can trust?

Join the 580.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading